Cardiff Oncology CRDF announced robust efficacy data from an ongoing mid-stage study evaluating two doses of its lead ...

Cardiff Oncology plans to share additional clinical data from its onvansertib trial in the first half of 2025.

US biotech Cardiff Oncology has announced positive initial data from CRDF-004, a randomized, Phase II trial evaluating ...

Initial results from randomized Phase 2 CRDF-004 trial evaluating onvansertib + standard of care in RAS-mut mCRC demonstrated ...

Cardiff Oncology’s investigational PLK1 inhibitor paired with standard-of-care treatment showed a 64% overall response rate ...

Cardiff Oncology's promising Phase 2 trial data for Onvansertib in colorectal cancer may lead to accelerated FDA approval, ...

An update from Cardiff Oncology ( (CRDF) ) is now available. Cardiff Oncology has reported promising initial results from its ...

(RTTNews) - w Inc. (CRDF), a clinical-stage biotechnology company, on Tuesday said it has priced its underwritten offering of about 15.385 ...

An exploratory analysis of the KEYNOTE-522 study presented at the 2024 San Antonio Breast Cancer Symposium highlights ...

他们发现，突变的RAS协助启动了一系列涉及特定核蛋白运输的事件，进而导致肿瘤不受控制地生长。这项成果于2024年11月11日发表在《Nature Cancer》杂志上。 RAS基因是癌症中经常突变的基因之一，突变的RAS蛋白是一些致命癌症的关键驱动因素，包括几乎所有的胰腺 ...

PHILADELPHIA — New research provides more evidence that glucagon-like peptide 1 receptor agonists (GLP-1 RAs) do not increase the risk for pancreatic cancer. Instead, the large electronic health ...

Over 35 years ago, a group led by Dr. Lowy contributed to the early studies that identified RAS as a cancer-causing gene and ...